

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



美瑞健康国际产业集团

Meilleure Health International Industry Group

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED

美瑞健康國際產業集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the announcement (the “**Announcement**”) of Meilleure Health International Industry Group Limited (the “**Company**”) relating to the discloseable transactions in relation to further disposals of listed securities dated 10 January 2024. Unless defined otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company would like to supplement that the highest applicable ratio (as defined in the Listing Rules) in respect of the Previous Transactions is less than 5% in aggregate. Accordingly, the Previous Transactions, on a standalone basis, do not constitute discloseable transactions of the Company under Chapter 14 of the Listing Rules.

Save as disclosed above, all other information set out in the Announcement remains unchanged. This announcement is supplemental to and should be read in conjunction with the Announcement.

By Order of the Board

Meilleure Health International Industry Group Limited

Zhou Wen Chuan

Executive Director and Chief Executive Officer

Hong Kong, 11 January 2024

As at the date of this announcement, the Board comprises Mr. Zhou Xuzhou, Dr. Zeng Wentao and Ms. Zhou Wen Chuan as executive Directors, Dr. Mao Zhenhua as non-executive Director and Professor Chau Chi Wai, Wilton, Dr. Yang Yu and Mr. Wu Peng as independent non-executive Directors.